Startups
Vidac is a clinical stage innovative biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncology and dermatology ailments. We at Vidac are passionate about transforming breakthrough science into innovative therapies to address major unmet medical needs.
Our breakthrough technology targets the VDAC/HK2 system that is unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue, thus holds the promise of delivering first-in-class drugs that are both efficacious and well tolerated by patients.
Our breakthrough technology targets the VDAC/HK2 system that is unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue, thus holds the promise of delivering first-in-class drugs that are both efficacious and well tolerated by patients.
Overview
Location
Israel, Center District, Nes Ziona
Employees
11-50
Phone
+972 2-595-2090
Total raised
$9M
Founded date
2011
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 16
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 15, 2026 | Vidac Pharma Announces Completion of Patient Enrollment in Phase 2B Study of VDA-1102 for High-Risk Actinic Keratosis | All 39 patients enrolled; follow-up continues as planned vidac Pharma Holdings Plc (Xetr:XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) The completion of patient enrollment in this Phase 2B study represents an important milestone in the cli... |
| May 13, 2026 | Vidac Pharma in Advanced Negotiations to Join Quest for Health and Expand into Strasbourg | Company evaluating strategic expansion into leading European life sciences and innovation ecosystem Vidac pharma Holdings Plc (Xtra:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) We believe that establishing a presence within Quest for Health c... |
| Apr 21, 2026 | Strategic Expansion into Continental Europe | Vidac Pharma explores European expansion and potential spin-off to strengthen market access, partnerships, and growth opportunities Vidac Pharma Holdings Plc. (Xetr:XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) We believe that establishing... |
| Mar 11, 2026 | Financial Support by Main Shareholders and Directors of Vidac Pharma Holding PLC | Vidac Pharma Holdings Plc. (XETR:XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ))LONDON, UNITED KINGDOM, March 11, 2026 /EINPresswire.com/ -- Vidac Pharma Holdings Plc. announces that in order to accelerate the development efforts of Vidac P... |
| Feb 11, 2026 | Vidac Pharma Initiates In Vivo Pre-Clinical Program in Psoriasis, Expanding Its HK2/VDAC Platform Beyond Oncology | Study to be conducted by PharmaLegacy, a leading Contract Research Organization The scientific rationale for evaluating our HK2/VDAC platform in psoriasis is compelling” — Dr. Max HerzbergLONDON, UNITED KINGDOM, February 11, 2026 /EINPressw... |
| Jan 12, 2026 | Vidac Pharma Receives Notice of Issuance from USPTO for One of Its Core Patents | Vidac pharma Holding Plc (Xtra:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) This patent issuance represents an important milestone for Vidac Pharma. It strengthens the protection of our novel small chemical entities targeting HK2–mitochondria... |
| Sep 15, 2025 | Vidac Pharma Submits Clinical Study Application to EMA for Advanced Actinic Keratosis Lesions | Comprehensive dossier underscores rigorous scientific, clinical, and CMC preparation, with key support from CRO partners Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) Our Phase 2 research trial is designed to ref... |
| Sep 2, 2025 | Sphene Equity Research Update Reaffirms “Buy” Rating on Vidac Pharma | Continued analyst endorsement underscores confidence in shareholder value and growth potential Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) Vidac is committed to advancing breakthrough therapies targeting the fu... |
| Jun 25, 2025 | Vidac Pharma Receives 'Buy' Rating and Increased Valuation from Sphene Capital, Underscoring Strong Growth Prospects | Sphene Capital Cites Strong Clinical Pipeline and Unique Approach to Tumor Microenvironment Disruption Vidac Pharma Plc (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) This independent 'Buy' rating reflects the strength of our pipelin... |
Show more
Reviews 0
FAQ about Vidac Pharma
When was Vidac Pharma founded?
Vidac Pharma was founded in 2011.
How much funding has Vidac Pharma raised?
Vidac Pharma has raised $9M in total across 1 funding round.
What has the press written about Vidac Pharma?
Parsers VC has collected 16 articles mentioning Vidac Pharma, among them “Vidac Pharma Announces Completion of Patient Enrollment in Phase 2B Study of VDA-1102 for High-Risk Actinic Keratosis” (Jun 15, 2026) and “Vidac Pharma in Advanced Negotiations to Join Quest for Health and Expand into Strasbourg” (May 13, 2026).
Is Vidac Pharma still active?
Yes, Vidac Pharma is active; its latest activity on Parsers VC dates from Jul 15, 2026.